Clinical Trial Update: Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase II trial comparing Afinitor to Sutent in metastatic non-clear cell renal cell carcinoma has completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-clear Cell Renal Cell Carcinoma

Drugs mentioned

• Afinitor (everolimus)
• Sutent (sunitinib)

Snippet

Sponsor: Duke University | Conditions: Advanced Non-clear Cell Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2016-06-20